Payment overview · 2025
General Payments
$276.60
13 reported records · 7 companies
Healthcare provider profile · identity verified
Miranda M Handyside
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · THREE RIVERS, MI · NPI 1427501378
Verified facts
What the public records show
CMS Open Payments records show Miranda M Handyside received $276.60 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 41.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $114.53 | 41.4% | 6 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $39.24 | 14.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.53 | 11.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.31 | 9.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $25.27 | 9.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.86 | 7.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.86 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $276.60 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.53 | 6 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $39.24 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.53 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 415 | 121 |
| Lisinopril | Lisinopril | 357 | 89 |
| Losartan Potassium | Losartan Potassium | 325 | 107 |
| Omeprazole | Omeprazole | 295 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 88 |
| Metformin Hcl | Metformin Hcl | 197 | 64 |
| Gabapentin | Gabapentin | 166 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 40 |
| Metformin Hcl Er | Metformin Hcl | 138 | 35 |
| Meloxicam | Meloxicam | 137 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 27 |
| Carvedilol | Carvedilol | 120 | 36 |
| Trazodone Hcl | Trazodone Hcl | 119 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 42 |
| Tramadol Hcl | Tramadol Hcl | 109 | 26 |
| Jardiance | Empagliflozin | 107 | 27 |
| Ozempic | Semaglutide | 107 | 29 |
| Potassium Chloride | Potassium Chloride | 106 | 28 |
| Pregabalin | Pregabalin | 105 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 42 |
| Januvia | Sitagliptin Phosphate | 91 | 25 |
| Furosemide | Furosemide | 90 | 36 |
| Simvastatin | Simvastatin | 82 | 29 |
| Famotidine | Famotidine | 79 | 21 |
| Sertraline Hcl | Sertraline Hcl | 79 | 24 |
| Alendronate Sodium | Alendronate Sodium | 77 | 21 |
| Allopurinol | Allopurinol | 74 | 22 |
| Farxiga | Dapagliflozin Propanediol | 73 | 25 |
| Mounjaro | Tirzepatide | 73 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 23 |
| Spironolactone | Spironolactone | 66 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 36 |
| Eliquis | Apixaban | 53 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 11 |
| Ezetimibe | Ezetimibe | 50 | 15 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Montelukast Sodium | Montelukast Sodium | 43 | 16 |
| Finasteride | Finasteride | 42 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 16 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | 11 |
| Torsemide | Torsemide | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 15 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 11 |
| Atenolol | Atenolol | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | 11 |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Dutasteride | Dutasteride | 23 | 12 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Prednisone | Prednisone | 21 | 15 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Lorazepam | Lorazepam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.60 · 13 records | GlaxoSmithKline, LLC. | JARDIANCE, LEQVIO, Monarch Platform, Ohtuvayre, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error